Pulmozyme Inhalation Solution 2.5 mg. 2.5 m_.. 1.0 mg/m_ Inhalation solution
PDF Leaflet Revision Date: 16 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Management of cystic fibrosis in patients over 5 years with FVC > 40%.
Dosage (summary)
2.5 mg once daily via nebulizer for patients u2265 5 years; some may benefit from twice daily.
Special Populations
- Children under 5 years
- Patients with FVC < 40%
Pregnancy & Breastfeeding
Safety not established in pregnancy; avoid in breastfeeding.
Key Drug Interactions
- Standard cystic fibrosis therapies can be used but not mixed in nebulizer.
Contraindications
- Hypersensitivity to dornase alfa
- Pregnancy
- Lactation
- Children < 5 years
Common side effects
- Conjunctivitis
- Dysphonia
- Dyspnoea
- Pharyngitis
- Cough
Counselling Points
- Inhale daily without breaks; do not mix with other medications in nebulizer.
Serious warnings
- Pulmonary function may decline upon initiation; monitor for antibody development.
Important Disclaimer
The Pulmozyme Inhalation Solution 2.5 mg. 2.5 m_.. 1.0 mg/m_ Inhalation solution professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
